Tyck till om SwePub Sök
här!
Sökning: onr:"swepub:oai:DiVA.org:uu-215079" >
Prognostic Biomarke...
Prognostic Biomarkers and Target Proteins for Treatment of High-grade Gliomas
-
- Sooman, Linda, 1983- (författare)
- Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap
-
- Ekman, Simon (preses)
- Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap
-
- Lennartsson, Johan (preses)
- Uppsala universitet,Ludwiginstitutet för cancerforskning
-
visa fler...
-
- Gullbo, Joachim (preses)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin,Institutionen för radiologi, onkologi och strålningsvetenskap
-
- Bergqvist, Michael (preses)
- Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap
-
- Blomquist, Erik (preses)
- Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap
-
- Bergström, Stefan (preses)
- Uppsala universitet,Centrum för klinisk forskning, Gävleborg
-
- Melin, Beatrice (opponent)
- Strålningsvetenskaper, Onkologi, Umeå universitet
-
visa färre...
-
(creator_code:org_t)
- ISBN 9789155488390
- Uppsala : Acta Universitatis Upsaliensis, 2014
- Engelska 74 s.
-
Serie: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1651-6206 ; 965
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://uu.diva-port... (Preview)
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- The survival for high-grade glioma patients is poor and the treatment may cause severe side effects. A common obstacle in the treatment is chemoresistance. To improve the quality of life and prolong survival for these patients prognostic biomarkers and new approaches for chemotherapy are needed. To this end, a strategy to evade chemoresistance was evaluated by combining chemotherapeutic drugs with agents inhibiting resistance mechanisms identified by a bioinformatic analysis (paper I). The prognostic value of 13 different proteins was analyzed in this thesis (papers II-IV). Two of them, p38 mitogen-activated protein kinase (MAPK) and protein tyrosine phosphatase non-receptor type 6 (PTPN6, also known as SHP1) were analyzed for their potential as targets in combination chemotherapy (in paper III and IV, respectively). We found that:PTPN6 expression and methylation status may be important for survival of anaplastic glioma patients, p38 MAPK phosphorylation may be a potential negative prognostic biomarker for high-grade glioma patients and FGF2 expression may be a potential negative prognostic biomarker for proneural glioma patients.PTPN6 may be a useful target for combination chemotherapy with cisplatin, melphalan or bortezomib in high-grade gliomas. The following drug combinations; camptothecin combined with an EGFR or RAC1 inhibitor, imatinib combined with a Notch or RAC1 inhibitor, temozolomide combined with an EGFR or FAK inhibitor and vandetanib combined with a p38 MAPK inhibitor may be useful combination chemotherapy for high-grade gliomas.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- High-grade glioma
- prognostic biomarkers
- combination chemotherapy
- DNA methylation
- FGF2
- p38 MAPK
- PTPN6
- camptothecin
- imatinib
- vandetanib
- EGFR
- RAC1
- Notch
- Medical Science
- Medicinsk vetenskap
- Oncology
- Onkologi
Publikations- och innehållstyp
- vet (ämneskategori)
- dok (ämneskategori)
Hitta via bibliotek
Till lärosätets databas